Stacey R. Slingerland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stacey R. Slingerland has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Nadine Schulz
Catharina Heart Centre, Catharina Hospital , P.O. Box 1350, Eindhoven 5602 ZA
5 shared publications - Dennis van Veghel
Catharina Heart Centre, Catharina Hospital , P.O. Box 1350, Eindhoven 5602 ZA
5 shared publications - Gijs J. van Steenbergen
Catharina Heart Center, Catharina Hospital, Eindhoven, The Netherlands
5 shared publications - Lukas Dekker
Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands
4 shared publications Daniela N. Schulz
Catharina Hosp, Catharina Heart Ctr, Res & Dev Dept, Eindhoven, Netherlands
2 shared publicationsDennis van Veghel
Catharina Ziekenhuis, Hart- en vaatcentrum, Eindhoven
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Improved patient value after implementing same day discharge for patients undergoing pulmonary vein isolation
Aims: Pulmonary vein isolation (PVI) is an effective intervention to treat atrial fibrillation, which is increasingly prevalent. Same-day discharge (SDD) is a strategic approach to limit procedure-related costs. This study aimed to compare healthcare utilization, costs, and clinical outcomes before and after implementation of an SDD protocol. Methods and results: This retrospective study included 2987 patients undergoing PVI between 1 January 2016 and 1 April 2021. Baseline characteristics, pre-, peri-, and post-procedure healthcare utilization and clinical outcomes were compared before (cohort A; n = 1379) and after (Cohort B; n = 1608) implementation of the SDD protocol using bivariate and multivariate analyses. show that cohort B vs. cohort A had lower all-cause 90-day mortality (0% vs. 0.3%, P = 0.031), no differences in re-ablation < 1 year (P = 0.286), as well as in complications: bleedings (P = 0.177), tamponade < 30 days (P = 0.157), phrenic nerve injury (P = 0.984), thromboembolic complication < 72 h (P = 0.212), or vascular complications (P = 0.290). In terms of healthcare utilization and costs, cohort B had significantly less peri-procedure hospital admission costs (€721.52 vs. €1011.78, P < 0.001) and less total peri- and post-procedure costs (€840.37 vs. €1152.94, P < 0.001). Adjusted for all baseline characteristics, the post-implementation cohort showed on average €315 lower total costs per patient. Conclusion: The implementation of the SDD protocol was associated with comparable complication rates while significantly reducing both peri- and post-procedure healthcare utilization and costs, thereby enhancing patient value. This indicates a potential margin for further cost reductions and increased efficiency.
- 1 October 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessImproved patient value after implementing same day discharge for patients undergoing pulmonary vein isolation
Aims: Pulmonary vein isolation (PVI) is an effective intervention to treat atrial fibrillation, which is increasingly prevalent. Same-day discharge (SDD) is a strategic approach to limit procedure-related costs. This study aimed to compare healthcare utilization, costs, and clinical outcomes before and after implementation of an SDD protocol. Methods and results: This retrospective study included 2987 patients undergoing PVI between 1 January 2016 and 1 April 2021. Baseline characteristics, pre-, peri-, and post-procedure healthcare utilization and clinical outcomes were compared before (cohort A; n = 1379) and after (Cohort B; n = 1608) implementation of the SDD protocol using bivariate and multivariate analyses. show that cohort B vs. cohort A had lower all-cause 90-day mortality (0% vs. 0.3%, P = 0.031), no differences in re-ablation < 1 year (P = 0.286), as well as in complications: bleedings (P = 0.177), tamponade < 30 days (P = 0.157), phrenic nerve injury (P = 0.984), thromboembolic complication < 72 h (P = 0.212), or vascular complications (P = 0.290). In terms of healthcare utilization and costs, cohort B had significantly less peri-procedure hospital admission costs (€721.52 vs. €1011.78, P < 0.001) and less total peri- and post-procedure costs (€840.37 vs. €1152.94, P < 0.001). Adjusted for all baseline characteristics, the post-implementation cohort showed on average €315 lower total costs per patient. Conclusion: The implementation of the SDD protocol was associated with comparable complication rates while significantly reducing both peri- and post-procedure healthcare utilization and costs, thereby enhancing patient value. This indicates a potential margin for further cost reductions and increased efficiency.
- Open Access
- 19 June 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 68 (6) , 1351-1357
Same-day discharge versus overnight stay after pulmonary vein isolation: an assessment on clinical outcomes and healthcare utilization
Background: Atrial fibrillation is increasingly prevalent and constitutes a severe economic and clinical burden. Pulmonary vein isolation (PVI) is an effective treatment. Evidence on the safety of same-day discharge (SDD) after PVI, instead of overnight stay (ONS), is limited. Methods and results: This retrospective study uses data from PVI’s performed between June 2018 and December 2020 in the Netherlands. Baseline characteristics, clinical outcome data, and healthcare utilization, extracted from two national databases, were compared between the implementation of an SDD protocol in a single center and a national benchmark where the majority is an ONS strategy. Descriptive and bivariate analyses were performed. We included data from 11,812 PVI’s,1360 in the SDD protocol group, and 10,452 for the ONS benchmark. The SDD protocol group performed 57.7% of PVI’s in SDD, while the benchmark performed 5.3% (p < 0.001). The SDD protocol group performed more cryoballoon PVI (90.8% vs. 39.2%, p < 0.001). There were no differences in bleeding (p = 0.830), thromboembolic (p = 0.893), vascular complications (p = 0.720), or cardiac tamponade (p = 0.634). Peri-procedural hospital stay was significantly shorter in the SDD protocol group (0.50 day vs. 1.52 days, p < 0.001), without a reallocation of health care to outpatient clinic (p = 0.230), emergency department (p = 0.132), or a higher rate of readmission (p = 0.092). Conclusion: The SDD protocol group with 57.7% SDD has similar complication rates and lower healthcare utilization, compared to the national ONS benchmark with 5.3% SDD, indicating that the SDD protocol is a safe and effective alternative for ONS in patients undergoing PVI. The implementation of an SDD protocol results suggests a potential reduction of nationwide healthcare utilization. Graphical
- 19 June 2025
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 68 (6) , 1351-1357
Open AccessSame-day discharge versus overnight stay after pulmonary vein isolation: an assessment on clinical outcomes and healthcare utilization
Background: Atrial fibrillation is increasingly prevalent and constitutes a severe economic and clinical burden. Pulmonary vein isolation (PVI) is an effective treatment. Evidence on the safety of same-day discharge (SDD) after PVI, instead of overnight stay (ONS), is limited. Methods and results: This retrospective study uses data from PVI’s performed between June 2018 and December 2020 in the Netherlands. Baseline characteristics, clinical outcome data, and healthcare utilization, extracted from two national databases, were compared between the implementation of an SDD protocol in a single center and a national benchmark where the majority is an ONS strategy. Descriptive and bivariate analyses were performed. We included data from 11,812 PVI’s,1360 in the SDD protocol group, and 10,452 for the ONS benchmark. The SDD protocol group performed 57.7% of PVI’s in SDD, while the benchmark performed 5.3% (p < 0.001). The SDD protocol group performed more cryoballoon PVI (90.8% vs. 39.2%, p < 0.001). There were no differences in bleeding (p = 0.830), thromboembolic (p = 0.893), vascular complications (p = 0.720), or cardiac tamponade (p = 0.634). Peri-procedural hospital stay was significantly shorter in the SDD protocol group (0.50 day vs. 1.52 days, p < 0.001), without a reallocation of health care to outpatient clinic (p = 0.230), emergency department (p = 0.132), or a higher rate of readmission (p = 0.092). Conclusion: The SDD protocol group with 57.7% SDD has similar complication rates and lower healthcare utilization, compared to the national ONS benchmark with 5.3% SDD, indicating that the SDD protocol is a safe and effective alternative for ONS in patients undergoing PVI. The implementation of an SDD protocol results suggests a potential reduction of nationwide healthcare utilization. Graphical
- Open Access
Same-day discharge versus overnight stay after pulmonary vein isolation: an assessment on clinical outcomes and healthcare utilization
Background: Atrial fibrillation is increasingly prevalent and constitutes a severe economic and clinical burden. Pulmonary vein isolation (PVI) is an effective treatment. Evidence on the safety of same-day discharge (SDD) after PVI, instead of overnight stay (ONS), is limited. Methods & results: This retrospective study uses data from PVI’s performed between June 2018 and December 2020 in the Netherlands. Baseline characteristics, clinical outcome data and health care utilization, extracted from two national databases, were compared between the implementation of an SDD protocol in a single centre and a national benchmark where majority is an ONS strategy. Descriptive and bivariate analyses were performed. We included data from 11,812 PVI’s; 1,360 in the SDD group and 10,452 for the ONS benchmark. The SDD protocol group performed 57.7% of PVI’s in SDD, the benchmark 5.3% (p<.001). The SDD protocol group performed more cryoballoon PVI (90.8% vs. 39.2%, p<.001). There were no differences in bleeding (p=.830), thromboembolic (p=.893) or vascular complications (p=.720), or cardiac tamponade (p=.634). Peri-procedural hospital stay was significantly shorter in the SDD protocol group (0.50 day vs. 1.52 days, p<.001), without a reallocation of healthcare to outpatient clinic (p=.230), emergency department (p=.132) or higher rate of readmission (p=.092). Conclusion: The SDD protocol group with 57.7% SDD has similar complication rates and lower health care utilization, compared to the national ONS benchmark with 5.3% SDD, indicating that SDD is a safe and effective alternative for ONS in patients undergoing PVI. The 5.3% ONS in the benchmark suggests a potential reduction of nationwide healthcare utilization.
Open AccessSame-day discharge versus overnight stay after pulmonary vein isolation: an assessment on clinical outcomes and healthcare utilization
Background: Atrial fibrillation is increasingly prevalent and constitutes a severe economic and clinical burden. Pulmonary vein isolation (PVI) is an effective treatment. Evidence on the safety of same-day discharge (SDD) after PVI, instead of overnight stay (ONS), is limited. Methods & results: This retrospective study uses data from PVI’s performed between June 2018 and December 2020 in the Netherlands. Baseline characteristics, clinical outcome data and health care utilization, extracted from two national databases, were compared between the implementation of an SDD protocol in a single centre and a national benchmark where majority is an ONS strategy. Descriptive and bivariate analyses were performed. We included data from 11,812 PVI’s; 1,360 in the SDD group and 10,452 for the ONS benchmark. The SDD protocol group performed 57.7% of PVI’s in SDD, the benchmark 5.3% (p<.001). The SDD protocol group performed more cryoballoon PVI (90.8% vs. 39.2%, p<.001). There were no differences in bleeding (p=.830), thromboembolic (p=.893) or vascular complications (p=.720), or cardiac tamponade (p=.634). Peri-procedural hospital stay was significantly shorter in the SDD protocol group (0.50 day vs. 1.52 days, p<.001), without a reallocation of healthcare to outpatient clinic (p=.230), emergency department (p=.132) or higher rate of readmission (p=.092). Conclusion: The SDD protocol group with 57.7% SDD has similar complication rates and lower health care utilization, compared to the national ONS benchmark with 5.3% SDD, indicating that SDD is a safe and effective alternative for ONS in patients undergoing PVI. The 5.3% ONS in the benchmark suggests a potential reduction of nationwide healthcare utilization.
- 26 September 2024
- Vol. 168
[Are medical professionals allowed to share data from patient health records with clinical quality registries in the Netherlands?].
This study examines, from a legal standpoint, the conditions under which patient data may be shared and processed by clinical quality registries in the Netherlands and investigates the potential impact of the proposed changes of the Healthcare Quality, Complaints and Disputes Act (WKKGZ) on these practices. Healthcare providers in the Netherlands may share patient data with clinical quality registries to measure and improve care quality, provided they have explicit patient consent or a legal basis. While there is general consensus within the field, legal ambiguity remains regarding processing data without explicit consent. Proposed changes to the WKKGZ would create an explicit legal basis for clinical quality registries to collect and process patient data without explicit consent, aiming to improve to improve the quality of care for the greater public interest.
- 26 September 2024
- Vol. 168
[Are medical professionals allowed to share data from patient health records with clinical quality registries in the Netherlands?].
This study examines, from a legal standpoint, the conditions under which patient data may be shared and processed by clinical quality registries in the Netherlands and investigates the potential impact of the proposed changes of the Healthcare Quality, Complaints and Disputes Act (WKKGZ) on these practices. Healthcare providers in the Netherlands may share patient data with clinical quality registries to measure and improve care quality, provided they have explicit patient consent or a legal basis. While there is general consensus within the field, legal ambiguity remains regarding processing data without explicit consent. Proposed changes to the WKKGZ would create an explicit legal basis for clinical quality registries to collect and process patient data without explicit consent, aiming to improve to improve the quality of care for the greater public interest.
- Open Access
- 18 July 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-12
A high-volume study on the impact of diabetes mellitus on clinical outcomes after surgical and percutaneous cardiac interventions
Background: Type I and type II diabetes mellitus (DM) patients have a higher prevalence of cardiovascular diseases, as well as a higher mortality risk of cardiovascular diseases and interventions. This study provides an update on the impact of DM on clinical outcomes, including mortality, complications and reinterventions, using data on percutaneous and surgical cardiac interventions in the Netherlands. Methods: This is a retrospective, nearby nationwide study using real-world observational data registered by the Netherlands Heart Registration (NHR) between 2015 and 2020. Patients treated for combined or isolated coronary artery disease (CAD) and aortic valve disease (AVD) were studied. Bivariate analyses and multivariate logistic regression models were used to evaluate the association between DM and clinical outcomes both unadjusted and adjusted for baseline characteristics. Results: 241,360 patients underwent the following interventions; percutaneous coronary intervention(N = 177,556), coronary artery bypass grafting(N = 39,069), transcatheter aortic valve implantation(N = 11,819), aortic valve replacement(N = 8,028) and combined CABG and AVR(N = 4,888). The incidence of DM type I and II was 21.1%, 26.7%, 17.8%, 27.6% and 27% respectively. For all procedures, there are statistically significant differences between patients living with and without diabetes, adjusted for baseline characteristics, at the expense of patients with diabetes for 30-days mortality after PCI (OR = 1.68; p <.001); 120-days mortality after CABG (OR = 1.35; p <.001), AVR (OR = 1.5; p <.03) and CABG + AVR (OR = 1.42; p =.02); and 1-year mortality after CABG (OR = 1.43; p <.001), TAVI (OR = 1.21; p =.01) and PCI (OR = 1.68; p <.001). Conclusion: Patients with DM remain to have unfavourable outcomes compared to nondiabetic patients which calls for a critical reappraisal of existing care pathways aimed at diabetic patients within the cardiovascular field.
- 18 July 2024
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-12
Open AccessA high-volume study on the impact of diabetes mellitus on clinical outcomes after surgical and percutaneous cardiac interventions
Background: Type I and type II diabetes mellitus (DM) patients have a higher prevalence of cardiovascular diseases, as well as a higher mortality risk of cardiovascular diseases and interventions. This study provides an update on the impact of DM on clinical outcomes, including mortality, complications and reinterventions, using data on percutaneous and surgical cardiac interventions in the Netherlands. Methods: This is a retrospective, nearby nationwide study using real-world observational data registered by the Netherlands Heart Registration (NHR) between 2015 and 2020. Patients treated for combined or isolated coronary artery disease (CAD) and aortic valve disease (AVD) were studied. Bivariate analyses and multivariate logistic regression models were used to evaluate the association between DM and clinical outcomes both unadjusted and adjusted for baseline characteristics. Results: 241,360 patients underwent the following interventions; percutaneous coronary intervention(N = 177,556), coronary artery bypass grafting(N = 39,069), transcatheter aortic valve implantation(N = 11,819), aortic valve replacement(N = 8,028) and combined CABG and AVR(N = 4,888). The incidence of DM type I and II was 21.1%, 26.7%, 17.8%, 27.6% and 27% respectively. For all procedures, there are statistically significant differences between patients living with and without diabetes, adjusted for baseline characteristics, at the expense of patients with diabetes for 30-days mortality after PCI (OR = 1.68; p <.001); 120-days mortality after CABG (OR = 1.35; p <.001), AVR (OR = 1.5; p <.03) and CABG + AVR (OR = 1.42; p =.02); and 1-year mortality after CABG (OR = 1.43; p <.001), TAVI (OR = 1.21; p =.01) and PCI (OR = 1.68; p <.001). Conclusion: Patients with DM remain to have unfavourable outcomes compared to nondiabetic patients which calls for a critical reappraisal of existing care pathways aimed at diabetic patients within the cardiovascular field.
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (12) , 6395-6402
Measuring costs and outcomes: what are suitable models while implementing value-based healthcare in thoracic surgery?
Measuring costs and outcomes: what are suitable models while implementing value-based healthcare in thoracic surgery?
- 1 December 2023
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 15 (12) , 6395-6402
Open AccessMeasuring costs and outcomes: what are suitable models while implementing value-based healthcare in thoracic surgery?
Measuring costs and outcomes: what are suitable models while implementing value-based healthcare in thoracic surgery?
- Open Access
- 16 November 2023
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 82, 26-33
Results of systematic patient outcome monitoring: Does post-dilatation during angiography-guided percutaneous coronary intervention improve clinical outcomes?
- 16 November 2023
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 82, 26-33
Open AccessResults of systematic patient outcome monitoring: Does post-dilatation during angiography-guided percutaneous coronary intervention improve clinical outcomes?
- 1 September 2023
- Published by Taylor & Francis in International Journal of Healthcare Management
- Vol. 17 (4) , 869-879
The role of value-based healthcare in decision-making by executives in hospitals in the Netherlands: A nationwide evaluation
- 1 September 2023
- Published by Taylor & Francis in International Journal of Healthcare Management
- Vol. 17 (4) , 869-879
The role of value-based healthcare in decision-making by executives in hospitals in the Netherlands: A nationwide evaluation
- Open Access
- 31 March 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (6) , 716-723
Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
Progression of atrial fibrillation (AF) and outcomes of ablation therapy are strongly affected by modifiable risk factors. Although previous studies show beneficial effects of modifying single risk factors, there is lack of evidence from randomized controlled trials on the effects of integrated AF lifestyle programmes. The POP trial is designed to evaluate the clinical outcomes of a dedicated nurse-led AF lifestyle outpatient clinic in patients with symptomatic AF. This study is a prospective, 1:1 randomized, single centre, investigator-initiated clinical trial in 150 patients with paroxysmal or persistent AF referred for a first pulmonary vein isolation (PVI). Prior to the ablation, patients in the intervention group receive a personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic. Patient education and durable lifestyle management is promoted with an e-health platform. Patients in the control group receive standard care by cardiologists before ablation. The primary endpoint is the number of hospitalizations for re-ablation and cardioversion, with a follow-up of 12 months after ablation. Secondary endpoints include mortality, number of acute ischemic events, stroke or hospitalizations for heart failure, quality of life, number of ablations cancelled because of symptom reduction, and ablation success rate at 12 months. Determinants of patient and staff experience are explored and a cost-effectiveness analysis is included. The POP trial will help ascertain the efficacy and cost-effectiveness of an integrated technology-supported lifestyle therapy in patients with symptomatic AF. The trial is funded by the Netherlands Organisation for Health Research and Development [10070012010001]. Home sleep apnoea testing devices were provided by Itamar Medical, Ltd.ClinicalTrials.gov Identifier NCT05148338. Graphical abstract AF atrial fibrillation, OSA obstructive sleep apnoea, PFA pulsed field ablation, PVI pulmonary vein isolation.
- 31 March 2023
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (6) , 716-723
Open AccessImproving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
Progression of atrial fibrillation (AF) and outcomes of ablation therapy are strongly affected by modifiable risk factors. Although previous studies show beneficial effects of modifying single risk factors, there is lack of evidence from randomized controlled trials on the effects of integrated AF lifestyle programmes. The POP trial is designed to evaluate the clinical outcomes of a dedicated nurse-led AF lifestyle outpatient clinic in patients with symptomatic AF. This study is a prospective, 1:1 randomized, single centre, investigator-initiated clinical trial in 150 patients with paroxysmal or persistent AF referred for a first pulmonary vein isolation (PVI). Prior to the ablation, patients in the intervention group receive a personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic. Patient education and durable lifestyle management is promoted with an e-health platform. Patients in the control group receive standard care by cardiologists before ablation. The primary endpoint is the number of hospitalizations for re-ablation and cardioversion, with a follow-up of 12 months after ablation. Secondary endpoints include mortality, number of acute ischemic events, stroke or hospitalizations for heart failure, quality of life, number of ablations cancelled because of symptom reduction, and ablation success rate at 12 months. Determinants of patient and staff experience are explored and a cost-effectiveness analysis is included. The POP trial will help ascertain the efficacy and cost-effectiveness of an integrated technology-supported lifestyle therapy in patients with symptomatic AF. The trial is funded by the Netherlands Organisation for Health Research and Development [10070012010001]. Home sleep apnoea testing devices were provided by Itamar Medical, Ltd.ClinicalTrials.gov Identifier NCT05148338. Graphical abstract AF atrial fibrillation, OSA obstructive sleep apnoea, PFA pulsed field ablation, PVI pulmonary vein isolation.